Acta Medica Okayama 74巻 2号
2020-04 発行
Abe, Yoshiyuki
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
Fujibayashi, Kazutoshi
Medical Technology Innovation Center, Juntendo University
Nishizaki, Yuji
Medical Technology Innovation Center, Juntendo University
Yanagisawa, Naotake
Medical Technology Innovation Center, Juntendo University
Nojiri, Shuko
Medical Technology Innovation Center, Juntendo University
Kon, Takayuki
Department of Internal Medicine and Rheumatology, Juntendo University Nerima Hospital
Tada, Kurisu
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
Yamaji, Ken
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
Tamura, Naoto
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine
Glucocorticoids (GCs) have long played a central role in the treatment of systemic lupus erythematosus (SLE), but these drugs have many adverse effects. We will determine whether rapid weekly GC tapering is non-inferior to conventional biweekly tapering in patients with severe SLE. This is a randomized, open-label, multicenter controlled trial. The primary outcome is the relapse-free survival rate at 52 weeks. The main secondary outcome is the prevalence of the Lupus Low Disease Activity State at 52 weeks. The trial will determine the optimal method of tapering GCs in patients with severe SLE.
systemic lupus erythematosus
relapse-free survival rate
glucocorticoid, tapering
Lupus Low Disease
Activity State